{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:26:58Z","timestamp":1787218018312,"version":"build-2736575974"},"reference-count":86,"publisher":"Portland Press Ltd.","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boston Children's Hospital","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"HHS | National Institutes of Health","award":["R01CA255216"],"award-info":[{"award-number":["R01CA255216"]}]},{"name":"HHS | National Institutes of Health","award":["R01AI182177"],"award-info":[{"award-number":["R01AI182177"]}]},{"name":"HHS | National Institutes of Health","award":["R24OD035556"],"award-info":[{"award-number":["R24OD035556"]}]},{"name":"Charles H. Hood Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"National Multiple Sclerosis Society","award":["TA-2205-39479"],"award-info":[{"award-number":["TA-2205-39479"]}]},{"name":"Rheumatology Research Foundation","award":["1257139"],"award-info":[{"award-number":["1257139"]}]},{"name":"Lupus Research Alliance","award":["1315119"],"award-info":[{"award-number":["1315119"]}]},{"name":"American Lung Association","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"American Heart Association","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"American Academy of Allergy Asthma and Immunology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Breakthrough T1D","award":["5-CDA-2025-1681-S-B"],"award-info":[{"award-number":["5-CDA-2025-1681-S-B"]}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fc\u03b3 receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.<\/jats:p>","DOI":"10.1042\/bst20250554","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:03:53Z","timestamp":1787216633000},"page":"1117-1130","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fc-engineering for improved cancer immunotherapy"],"prefix":"10.1042","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8570-1686","authenticated-orcid":false,"given":"Ella","family":"Borgman","sequence":"first","affiliation":[{"name":"1Harvard College, Cambridge, Massachusetts, U.S.A."},{"name":"2Division of Immunology, Boston Children\u2019s Hospital, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5115","authenticated-orcid":false,"given":"Camille","family":"Le Gall","sequence":"additional","affiliation":[{"name":"2Division of Immunology, Boston Children\u2019s Hospital, Boston, Massachusetts, U.S.A."},{"name":"3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-6071","authenticated-orcid":false,"given":"Hidde","family":"Ploegh","sequence":"additional","affiliation":[{"name":"4Program in Cellular and Molecular Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-1265","authenticated-orcid":false,"given":"Novalia","family":"Pishesha","sequence":"additional","affiliation":[{"name":"2Division of Immunology, Boston Children\u2019s Hospital, Boston, Massachusetts, U.S.A."},{"name":"3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082005034945000_B1","doi-asserted-by":"publisher","first-page":"1533796","DOI":"10.3389\/fimmu.2025.1533796","article-title":"Six events that shaped antibody approvals in oncology","volume":"16","author":"Paul","year":"2025","journal-title":"Front. Immunol."},{"key":"2026082005034945000_B2","article-title":"Therapeutic monoclonal antibodies approved or in regulatory review","author":"The Antibody Society"},{"key":"2026082005034945000_B3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/mabs.19909","article-title":"The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin","volume":"4","author":"Marks","year":"2012","journal-title":"MAbs"},{"key":"2026082005034945000_B4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am. J. Transplant."},{"key":"2026082005034945000_B5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antib8020030","article-title":"The ligands for human IgG and their effector functions","volume":"8","author":"De Taeye","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2026082005034945000_B6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J. Exp. Med."},{"key":"2026082005034945000_B7","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2026082005034945000_B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/imr.13265","article-title":"Antibody-mediated phagocytosis in cancer immunotherapy","volume":"319","author":"Van Wagoner","year":"2023","journal-title":"Immunol. Rev."},{"key":"2026082005034945000_B9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"2026082005034945000_B10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","article-title":"Cell contact-dependent priming and fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response","volume":"192","author":"Bartholomaeus","year":"2014","journal-title":"J. Immunol."},{"key":"2026082005034945000_B11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/blood-2014-08-593061","article-title":"Upregulation of Fc\u03b3RIIb on monocytes is necessary to promote the superagonist activity of TGN1412","volume":"125","author":"Hussain","year":"2015","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"2026082005034945000_B12","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026082005034945000_B13","doi-asserted-by":"publisher","first-page":"2039432","DOI":"10.1080\/2162402X.2022.2039432","article-title":"Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026082005034945000_B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026082005034945000_B15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2019.00529","article-title":"Role of the IgM Fc receptor in immunity and tolerance","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"key":"2026082005034945000_B16","volume-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2024","edition":"10th ed"},{"key":"2026082005034945000_B17","first-page":"63","article-title":"IgG Fc glycosylation in human immunity. Fc Mediated Activity of Antibodies: Structural and Functional Diversity","volume":"423","author":"Wang","year":"2019","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2026082005034945000_B18","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","article-title":"Engineering an IgG scaffold lacking effector function with optimized developability","volume":"292","author":"Jacobsen","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4161\/mabs.19941","article-title":"Quantitative evaluation of fucose reducing effects in a humanized antibody on Fc\u03b3 receptor binding and antibody-dependent cell-mediated cytotoxicity activities","volume":"4","author":"Chung","year":"2012","journal-title":"MAbs"},{"key":"2026082005034945000_B20","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PloS One"},{"key":"2026082005034945000_B21","doi-asserted-by":"publisher","first-page":"2402701","DOI":"10.1080\/19420862.2024.2402701","article-title":"Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors","volume":"16","author":"Hale","year":"2024","journal-title":"MAbs"},{"key":"2026082005034945000_B22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des.Sel."},{"key":"2026082005034945000_B23","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B24","doi-asserted-by":"publisher","first-page":"20167","DOI":"10.1073\/pnas.0809257105","article-title":"Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors","volume":"105","author":"Sazinsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"The Lancet"},{"key":"2026082005034945000_B26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"2026082005034945000_B27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"2026082005034945000_B28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/pbi.14260","article-title":"Plant-derived Durvalumab variants show efficient PD-1\/PD-L1 blockade and therapeutically favourable FcR binding","volume":"22","author":"Izadi","year":"2024","journal-title":"Plant Biotechnol. J."},{"key":"2026082005034945000_B29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol. Rev."},{"key":"2026082005034945000_B30","article-title":"TEVIMBRA (tislelizumab-jsgr) granted first FDA approval for esophageal squamous cell carcinoma","author":"Antibody Society","year":"2024","journal-title":"Antibody Society"},{"key":"2026082005034945000_B31","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"2026082005034945000_B32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"2026082005034945000_B33","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"2026082005034945000_B34","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling","volume":"3","author":"Yofe","year":"2022","journal-title":"Nat. Cancer"},{"key":"2026082005034945000_B35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"2026082005034945000_B36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"2026082005034945000_B37","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"2026082005034945000_B38","article-title":"Therapeutic monoclonal antibodies approved or in regulatory review","author":"The Antibody Society","year":"2025"},{"key":"2026082005034945000_B39","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026082005034945000_B40","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3324\/haematol.2024.285245","article-title":"Bispecific antibodies in follicular lymphoma","volume":"110","author":"Nizamuddin","year":"2024","journal-title":"Haematologica"},{"key":"2026082005034945000_B41","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B42","doi-asserted-by":"publisher","first-page":"17588359211020528","DOI":"10.1177\/17588359211020528","article-title":"Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors","volume":"13","author":"Liu","year":"2021","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"2026082005034945000_B43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40265-025-02160-6","article-title":"Iparomlimab and tuvonralimab: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"2026082005034945000_B44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"2026082005034945000_B45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026082005034945000_B46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"2026082005034945000_B47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng. Design Selection"},{"key":"2026082005034945000_B48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026082005034945000_B49","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat. Protoc."},{"key":"2026082005034945000_B50","doi-asserted-by":"publisher","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","article-title":"A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1","volume":"292","author":"De Nardis","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B51","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026082005034945000_B53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"2026082005034945000_B54","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"2026082005034945000_B55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol. Res. Treatment"},{"key":"2026082005034945000_B56","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc\u03b3RIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B57","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"2026082005034945000_B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J."},{"key":"2026082005034945000_B59","first-page":"883","article-title":"Mogamulizumab-kpkc: a novel therapy for the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Watson","year":"2019","journal-title":"J. Adv. Practitioner Oncol."},{"key":"2026082005034945000_B60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/LCTT.S337861","article-title":"Spotlight on amivantamab (JNJ-61186372) for EGFR exon 20 insertions positive non-small cell lung cancer","volume":"12","author":"Brazel","year":"2021","journal-title":"Lung Cancer"},{"key":"2026082005034945000_B61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"2026082005034945000_B62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/cancers15010038","article-title":"A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer","volume":"15","author":"Alasmari","year":"2022","journal-title":"Cancers"},{"key":"2026082005034945000_B63","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B64","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"2026082005034945000_B66","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B67","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2026082005034945000_B68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"Moore","year":"2010","journal-title":"MAbs"},{"key":"2026082005034945000_B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"2026082005034945000_B70","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","article-title":"An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"2026082005034945000_B71","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"2026082005034945000_B72","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s41467-023-39679-9","article-title":"Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial","volume":"14","author":"Spicer","year":"2023","journal-title":"Nat. Commun."},{"key":"2026082005034945000_B73","doi-asserted-by":"publisher","first-page":"e006948","DOI":"10.1136\/jitc-2023-006948","article-title":"IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models","volume":"11","author":"Stip","year":"2023","journal-title":"J. Immuno. Therapy Cancer"},{"key":"2026082005034945000_B74","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/cells14090632","article-title":"The efficacy of targeted monoclonal IgA antibodies against pancreatic ductal adenocarcinoma","volume":"14","author":"Raymakers","year":"2025","journal-title":"Cells"},{"key":"2026082005034945000_B75","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"2026082005034945000_B76","article-title":"HexaBody\u00ae antibody-technology platform","author":"Genmab","journal-title":"Genmab"},{"key":"2026082005034945000_B77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2015.12.007","article-title":"Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells","volume":"70","author":"Lindorfer","year":"2016","journal-title":"Mol. Immunol."},{"key":"2026082005034945000_B78","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/1535-7163.MCT-20-0044","article-title":"Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent antitumor activity through DR5 agonism","volume":"19","author":"Overdijk","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"2026082005034945000_B79","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/bloodadvances.2020003731","article-title":"Potent preclinical activity of HexaBody-DR5\/DR5 in relapsed and\/or refractory multiple myeloma","volume":"5","author":"van der Horst","year":"2021","journal-title":"Blood Adv."},{"key":"2026082005034945000_B80","article-title":"Study NCT03576131: \u201cGEN1029 (HexaBody\u00ae-DR5\/DR5) safety trial in patients with malignant solid tumors\u201d","author":"ClinicalTrials.gov"},{"key":"2026082005034945000_B81","doi-asserted-by":"publisher","first-page":"eadg9459","DOI":"10.1126\/sciimmunol.adg9459","article-title":"An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections","volume":"8","author":"Liu","year":"2023","journal-title":"Sci. Immunol."},{"key":"2026082005034945000_B82","doi-asserted-by":"publisher","first-page":"e2409565122","DOI":"10.1073\/pnas.2409565122","article-title":"A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections","volume":"122","author":"Harmand","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082005034945000_B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41551-025-01447-z","article-title":"Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy","volume":"10","author":"Liu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"2026082005034945000_B84","doi-asserted-by":"publisher","first-page":"2502673","DOI":"10.1080\/19420862.2025.2502673","article-title":"Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality","volume":"17","author":"Grandits","year":"2025","journal-title":"Mabs"},{"key":"2026082005034945000_B85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"2026082005034945000_B86","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1006\/jmbi.1997.1508","article-title":"Structure of an intact IgG1 monoclonal antibody","volume":"275","author":"Harris","year":"1998","journal-title":"J. Mol. Biol."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/54\/8\/1117\/991177\/bst-2025-0554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/54\/8\/1117\/991177\/bst-2025-0554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:03:57Z","timestamp":1787216637000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/54\/8\/1117\/237960\/Fc-engineering-for-improved-cancer-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":86,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8,26]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20250554","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]}}}